Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis

In treating allergic rhinitis (AR), montelukast has the potential to be used as an alternative or addition to oral antihistamine (OAH) or intranasal corticosteroid. Objectives: To assess the effectiveness of montelukast in treating AR. Methods: An electronic literature search was performed using...

Full description

Saved in:

Bibliographic Details
Main Author:	Krishna Moorthy, Madhusudhan
Format:	Thesis
Language:	English
Published:	2020
Subjects:	R Medicine (General)
Online Access:	http://eprints.usm.my/50044/1/MADHUSUDHAN%20AL%20KRISHNA%20MOORTHY-24%20pages.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.50044
record_format	uketd_dc
spelling	my-usm-ep.500442021-09-26T03:12:40Z Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis 2020 Krishna Moorthy, Madhusudhan R Medicine (General) In treating allergic rhinitis (AR), montelukast has the potential to be used as an alternative or addition to oral antihistamine (OAH) or intranasal corticosteroid. Objectives: To assess the effectiveness of montelukast in treating AR. Methods: An electronic literature search was performed using Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from 1966 to 21st January 2019. The eligibility criteria were randomized control trials comparing montelukast with placebo or other standard treatments. The primary outcomes assessed were daytime nasal symptom score (DNS) and nighttime nasal symptom score (NNS). The secondary outcomes assessed were composite nasal symptom score (CSS), daytime eyes symptom score (DES) and rhinoconjunctivitis quality of life questionnaires (RQLQ). Meta-analysis was done using Review Manager 5.3 software based on the random-effects model. Results: Fifteen studies of 10387 participants met the inclusion criteria. Montelukast was effective than placebo in improving DNS (MD -0.12, 95% CI -0.15 to -0.08; P < 0.001), NNS (MD -0.09, 95% CI -0.13 to -0.05; P < 0.001), CSS (MD -0.08, 95% CI -0.11 to -0.06; P < 0.001), DES (MD -0.17, 95% CI -0.33 to -0.02; P < 0.030) and RQLQ (MD -0.34, 95% CI - 0.49 to -0.20; P < 0.001). OAH was superior than montelukast in improving DNS (MD 0.08, 95% CI 0.03 to 0.13; P=0.002), CSS (MD 0.03, 95% CI -0.02 to 0.07; P=0.270), DES (MD 0.06, 95% CI 0 to 0.12; P=0.040) and RQLQ (MD 0.03, 95% CI -0.05 to 0.12; P=0.430). Montelukast was superior than OAH in improving NNS (MD -0.03, 95% CI -0.08 to 0.03; P=0.330). Intranasal fluticasone spray was superior than montelukast in improving DNS (MD 0.71, 95% CI 0.44 to 0.99; P < 0.001) and NNS (MD 0.63, 95% CI 0.29 to 0.97; P < 0.001). A combined montelukast and OAH was superior than OAH in in improving DNS vii (MD -0.15, 95% CI -0.27 to -0.03; P =0.010), NNS (MD -0.16, 95% CI -0.28 to -0.05; P =0.006), CSS (MD -0.12, 95% CI -0.25 to -0.01; P =0.070), DES (MD -0.12, 95% CI -0.30 to 0.06; P =0.180) and RQLQ (MD -0.10, 95% CI -0.28 to 0.08; P =0.290). A combined montelukast and OAH was superior than montelukast improving DNS (MD 0.15, 95% CI 0.08 to 0.21; P<0.001), NNS (MD 0.05, 95% CI -0.09 to 0.19; P=0.510), CSS (MD 0.1, 95% CI 0.03 to 0.17; P=0.007), DES (MD 0.18, 95% CI 0 to 0.36; P=0.050) and RQLQ (MD 0.07 95% CI -0.15 to 0.29; P=0.530). Conclusion: Montelukast is effective in treating AR patients with nocturnal symptoms and as add on combination therapy with OAH in the stepping up management of AR. 2020 Thesis http://eprints.usm.my/50044/ http://eprints.usm.my/50044/1/MADHUSUDHAN%20AL%20KRISHNA%20MOORTHY-24%20pages.pdf application/pdf en public phd doctoral Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	R Medicine (General)
spellingShingle	R Medicine (General) Krishna Moorthy, Madhusudhan Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis
description	In treating allergic rhinitis (AR), montelukast has the potential to be used as an alternative or addition to oral antihistamine (OAH) or intranasal corticosteroid. Objectives: To assess the effectiveness of montelukast in treating AR. Methods: An electronic literature search was performed using Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from 1966 to 21st January 2019. The eligibility criteria were randomized control trials comparing montelukast with placebo or other standard treatments. The primary outcomes assessed were daytime nasal symptom score (DNS) and nighttime nasal symptom score (NNS). The secondary outcomes assessed were composite nasal symptom score (CSS), daytime eyes symptom score (DES) and rhinoconjunctivitis quality of life questionnaires (RQLQ). Meta-analysis was done using Review Manager 5.3 software based on the random-effects model. Results: Fifteen studies of 10387 participants met the inclusion criteria. Montelukast was effective than placebo in improving DNS (MD -0.12, 95% CI -0.15 to -0.08; P < 0.001), NNS (MD -0.09, 95% CI -0.13 to -0.05; P < 0.001), CSS (MD -0.08, 95% CI -0.11 to -0.06; P < 0.001), DES (MD -0.17, 95% CI -0.33 to -0.02; P < 0.030) and RQLQ (MD -0.34, 95% CI - 0.49 to -0.20; P < 0.001). OAH was superior than montelukast in improving DNS (MD 0.08, 95% CI 0.03 to 0.13; P=0.002), CSS (MD 0.03, 95% CI -0.02 to 0.07; P=0.270), DES (MD 0.06, 95% CI 0 to 0.12; P=0.040) and RQLQ (MD 0.03, 95% CI -0.05 to 0.12; P=0.430). Montelukast was superior than OAH in improving NNS (MD -0.03, 95% CI -0.08 to 0.03; P=0.330). Intranasal fluticasone spray was superior than montelukast in improving DNS (MD 0.71, 95% CI 0.44 to 0.99; P < 0.001) and NNS (MD 0.63, 95% CI 0.29 to 0.97; P < 0.001). A combined montelukast and OAH was superior than OAH in in improving DNS vii (MD -0.15, 95% CI -0.27 to -0.03; P =0.010), NNS (MD -0.16, 95% CI -0.28 to -0.05; P =0.006), CSS (MD -0.12, 95% CI -0.25 to -0.01; P =0.070), DES (MD -0.12, 95% CI -0.30 to 0.06; P =0.180) and RQLQ (MD -0.10, 95% CI -0.28 to 0.08; P =0.290). A combined montelukast and OAH was superior than montelukast improving DNS (MD 0.15, 95% CI 0.08 to 0.21; P<0.001), NNS (MD 0.05, 95% CI -0.09 to 0.19; P=0.510), CSS (MD 0.1, 95% CI 0.03 to 0.17; P=0.007), DES (MD 0.18, 95% CI 0 to 0.36; P=0.050) and RQLQ (MD 0.07 95% CI -0.15 to 0.29; P=0.530). Conclusion: Montelukast is effective in treating AR patients with nocturnal symptoms and as add on combination therapy with OAH in the stepping up management of AR.
format	Thesis
qualification_name	Doctor of Philosophy (PhD.)
qualification_level	Doctorate
author	Krishna Moorthy, Madhusudhan
author_facet	Krishna Moorthy, Madhusudhan
author_sort	Krishna Moorthy, Madhusudhan
title	Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis
title_short	Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis
title_full	Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis
title_fullStr	Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis
title_full_unstemmed	Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis
title_sort	efficacy of montelukast in allergic rhinitis treatment: a systematic review and meta-analysis
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2020
url	http://eprints.usm.my/50044/1/MADHUSUDHAN%20AL%20KRISHNA%20MOORTHY-24%20pages.pdf
_version_	1747822021440438272

Efficacy of montelukast in allergic rhinitis Treatment: A systematic review and meta-analysis

Similar Items